OvaScience, Inc. (NASDAQ: OVAS)

Federman & Sherwood Investigates OvaScience, Inc. for Possible Breaches of Fiduciary Duty

Oklahoma City, OK (June 10, 2014) – The law firm of Federman & Sherwood has initiated an investigation into OvaScience, Inc. [NASDAQ: OVAS] with respect to alleged violations of the federal securities laws.

On September 10, 2013, the Company disclosed that it was suspending enrollment of the AUGMENT clinical trial in the United States after the Company received an untitled letter from the FDA questioning whether AUGMENT qualified for reduced regulatory oversight and advising the Company to file an Investigational New Drug application. Following this news, the Company’s shares dropped 23%, or $3.325 per share, to close at $10.95 per share on September 11, 2013. 

If you currently own common stock in OvaScience, Inc., have any information to assist in our investigation, or have questions or concerns regarding this notice or your rights or interests in this matter, please contact Federman & Sherwood, or complete the attached investor certification to be added to our database for this company. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases across the country.

Copyright © 2017 Federman & Sherwood. All Rights Reserved.